These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7517175)

  • 41. Relationships between drug concentrations in serum and CSF, clinical effects and monoaminergic variables in schizophrenic patients treated with sulpiride or chlorpromazine.
    Alfredsson G; Bjerkenstedt L; Edman G; Härnryd C; Oxenstierna G; Sedvall G; Wiesel FA
    Acta Psychiatr Scand Suppl; 1984; 311():49-74. PubMed ID: 6199949
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CSF amine metabolites, clinical symptoms, and body movement in psychiatric patients.
    Kirstein L; Bowers MB; Heninger G
    Biol Psychiatry; 1976 Aug; 11(4):421-34. PubMed ID: 963133
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CSF monoamine metabolites in depression and schizophrenia.
    Berger PA; Faull KF; Kilkowski J; Anderson PJ; Kraemer H; Davis KL; Barchas JD
    Am J Psychiatry; 1980 Feb; 137(2):174-80. PubMed ID: 7352572
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CSF creatinine in schizophrenia.
    Swahn CG; Sedvall G
    Biol Psychiatry; 1988 Mar; 23(6):586-94. PubMed ID: 2451543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
    van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
    Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls.
    Gerner RH; Fairbanks L; Anderson GM; Young JG; Scheinin M; Linnoila M; Hare TA; Shaywitz BA; Cohen DJ
    Am J Psychiatry; 1984 Dec; 141(12):1533-40. PubMed ID: 6209989
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reduction of MOPEG levels in cerebrospinal fluid of psychotic women after electroconvulsive treatment.
    Härnryd C; Bjerkenstedt L; Grimm VE; Sedvall G
    Psychopharmacology (Berl); 1979 Aug; 64(2):131-4. PubMed ID: 115032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor.
    Nagao T; Ohshimo T; Mitsunobu K; Sato M; Otsuki S
    Biol Psychiatry; 1979 Jun; 14(3):509-23. PubMed ID: 38867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 5-HIAA in cerebrospinal fluid and deficit schizophrenic characteristics.
    Csernansky JG; King RJ; Faustman WO; Moses JA; Poscher ME; Faull KF
    Br J Psychiatry; 1990 Apr; 156():501-7. PubMed ID: 1696842
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decrease in dopamine, its metabolites and noradrenaline in cerebrospinal fluid of schizophrenic patients after withdrawal of long-term neuroleptic treatment.
    Bagdy G; Perényi A; Frecska E; Révai K; Papp Z; Fekete MI; Arató M
    Psychopharmacology (Berl); 1985; 85(1):62-4. PubMed ID: 2580329
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cerebrospinal fluid levels of monoamine metabolites in panic disorder.
    Eriksson E; Westberg P; Alling C; Thuresson K; Modigh K
    Psychiatry Res; 1991 Mar; 36(3):243-51. PubMed ID: 1712114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cholecystokinin, dopamine and schizophrenia.
    Garver DL; Beinfeld MC; Yao JK
    Psychopharmacol Bull; 1990; 26(3):377-80. PubMed ID: 2274639
    [TBL] [Abstract][Full Text] [Related]  

  • 54. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
    Nagaoka S; Iwamoto N; Arai H
    Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and biochemical parameters during neuroleptic treatment. I. Investigations with haloperidol.
    Rüther E; Schilkrut R; Ackenheil M; Eben E; Hippius H
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jan; 9(1):33-6. PubMed ID: 981320
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monoamine metabolites in the CSF of epileptic patients.
    Laxer KD; Sourkes TL; Fang TY; Young SN; Gauthier SG; Missala K
    Neurology; 1979 Aug; 29(8):1157-61. PubMed ID: 37460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic, and healthy control subjects.
    Redmond DE; Katz MM; Maas JW; Swann A; Casper R; Davis JM
    Arch Gen Psychiatry; 1986 Oct; 43(10):938-47. PubMed ID: 2428328
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Seasonal variations of human lumbar CSF neurotransmitter metabolite concentrations.
    Losonczy MF; Mohs RC; Davis KL
    Psychiatry Res; 1984 May; 12(1):79-87. PubMed ID: 6205414
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aggression in humans correlates with cerebrospinal fluid amine metabolites.
    Brown GL; Goodwin FK; Ballenger JC; Goyer PF; Major LF
    Psychiatry Res; 1979 Oct; 1(2):131-9. PubMed ID: 95232
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dopamine metabolism and disposition in schizophrenic patients. Studies using debrisoquin.
    Maas JW; Contreras SA; Seleshi E; Bowden CL
    Arch Gen Psychiatry; 1988 Jun; 45(6):553-9. PubMed ID: 3377641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.